Autor:
Apablaza, G.
Montoya, L.
Morales-Verdejo, C.
Mellado, M.
Cuellar, M.
Lagos, C.F.
Soto-Delgado, J.
Chung, H.
Pessoa-Mahana, C.D.
Mella, J.
The beta(3) adrenergic receptor is raising as an important drug target for the treatment of pathologies such as diabetes, obesity, depression, and cardiac diseases among others. Several attempts to obtain selective and high affinity ligands have been made. Currently, Mirabegron is the only availa...
Enlace original:
http://repositorio.unab.cl/xmlui/handle/ria/4255
Apablaza, G.
,
Montoya, L.
,
Morales-Verdejo, C.
,
Mellado, M.
,
Cuellar, M.
,
Lagos, C.F.
,
Soto-Delgado, J.
,
Chung, H.
,
Pessoa-Mahana, C.D.
,
Mella, J.
,
[2D-QSAR and 3D-QSAR/CoMSIA studies on a series of (R)-2-((2-(1H-Indol-2-yl)ethyl)amino)-1-phenylethan-1-ol with human β3-adrenergic activity]
,
2D-QSAR and 3D-QSAR/CoMSIA studies on a series of (R)-2-((2-(1H-Indol-2-yl)ethyl)amino)-1-phenylethan-1-ol with human β3-adrenergic activity
